Cargando…
Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases require...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590000/ https://www.ncbi.nlm.nih.gov/pubmed/37864216 http://dx.doi.org/10.1186/s12916-023-03080-6 |
_version_ | 1785123905560641536 |
---|---|
author | Jia, Yu Li, Dongze You, Yi Yu, Jing Jiang, Wenli Liu, Yi Zeng, Rui Wan, Zhi Lei, Yi Liao, Xiaoyang |
author_facet | Jia, Yu Li, Dongze You, Yi Yu, Jing Jiang, Wenli Liu, Yi Zeng, Rui Wan, Zhi Lei, Yi Liao, Xiaoyang |
author_sort | Jia, Yu |
collection | PubMed |
description | BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification. METHODS: After propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections. RESULTS: Participants aged 59 (51–64) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid–base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results. CONCLUSIONS: Individuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-023-03080-6. |
format | Online Article Text |
id | pubmed-10590000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105900002023-10-22 Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank Jia, Yu Li, Dongze You, Yi Yu, Jing Jiang, Wenli Liu, Yi Zeng, Rui Wan, Zhi Lei, Yi Liao, Xiaoyang BMC Med Research Article BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification. METHODS: After propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections. RESULTS: Participants aged 59 (51–64) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid–base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results. CONCLUSIONS: Individuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-023-03080-6. BioMed Central 2023-10-20 /pmc/articles/PMC10590000/ /pubmed/37864216 http://dx.doi.org/10.1186/s12916-023-03080-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Jia, Yu Li, Dongze You, Yi Yu, Jing Jiang, Wenli Liu, Yi Zeng, Rui Wan, Zhi Lei, Yi Liao, Xiaoyang Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank |
title | Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank |
title_full | Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank |
title_fullStr | Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank |
title_full_unstemmed | Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank |
title_short | Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank |
title_sort | multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the uk biobank |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590000/ https://www.ncbi.nlm.nih.gov/pubmed/37864216 http://dx.doi.org/10.1186/s12916-023-03080-6 |
work_keys_str_mv | AT jiayu multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT lidongze multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT youyi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT yujing multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT jiangwenli multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT liuyi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT zengrui multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT wanzhi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT leiyi multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank AT liaoxiaoyang multisystemdiseasesanddeathtrajectoryofmetabolicdysfunctionassociatedfattyliverdiseasefindingsfromtheukbiobank |